No sooner does the news break that pharmaceutical giant GlaxoSmithKline deliberately withheld critical data which revealed that their diabetes drug Avandia significantly increased the risk of heart attacks amongst its largest users – senior citizens, today we received word that the company is paying $750 million to settle criminal and civil complaints linked to the … Continue reading
As you already know, there is no shortage of newsworthy information that crosses my virtual (and even physical) desk on a daily basis. When combined with my undeniably insatiable curiosity, this usually means that I could spend 25 hours a day and 8 days per week writing, or on the radio talking with a notable … Continue reading
HP “Buyer Incentives” and Off-Label Prescription Sales: Are there any good apples left to spoil the maleficence barrel?
“In many foreign countries, particularly in those with developing economies, it is common to engage in business practices that are prohibited by laws and regulations applicable to us, such as the Foreign Corrupt Practices Act. Although we implement policies and procedures designed to facilitate compliance with these laws, our employees, contractors and agents, as well … Continue reading
AstraZeneca $520 Million Settlement Underlines the Greed Over Good Mentality Within the Pharmaceutical Industry
Talk about a story having legs, in a December 2009 post titled “Antipsychotic Prescriptions . . . for Children: Is the Medicaid Story Today’s Version of Go Ask Alice?” I wrote about the startling revelation that the prescription of anti psychotic drugs to children between the ages of 3 and 17 was at an all time … Continue reading
“In the federal suit, Johnson & Johnson is accused not just of promoting Risperdal for patients without psychosis but of providing kickbacks to Omnicare, a middleman that supplied drugs to nursing homes and advised doctors what to prescribe. Last fall, Omnicare settled its part of the suit for $98 million.” The Boston Globe, Monday March … Continue reading